Search

Displaying results 2841 - 2850 of 8697 in total
  1. Drug

    Synthetic Conjugated Estrogens, B

    go.drugbank.com/drugs/DB09318
    Approved

    This shift in hormone production is largely responsible for many of the symptoms experienced during and after menopause and includes hot flashes and other vasomotor symptoms, painful intercourse, vaginal … This blend of ten estrogen derivatives are plant-derived forms of endogenous estrogens and contain many of the same compounds as the Conjugated Equine Estrogens (CEEs), although they are not considered

    Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP3A Substrates
  2. Drug

    Zidebactam

    go.drugbank.com/drugs/DB13090
    Approved

    [L63932] Wockhardt announced FDA approval of the cefepime-zidebactam combination on May 30, 2026, for adults with complicated urinary tract infections, including pyelonephritis, caused by designated … [L63350,L63932] The combination is aimed at multidrug-resistant Gram-negative infections, a group for which treatment options are limited and where resistance to carbapenems has narrowed the available

    Categories: Antibacterials for Systemic Use, Antiinfectives for Systemic Use
  3. Drug

    Clodronic acid

    go.drugbank.com/drugs/DB00720
    ApprovedInvestigationalVet approved

    Clodronic acid is a first generation bisphosphonate similar to etidronic acid and tiludronic acid. These drugs were developed to mimic the action of pyrophosphate, a regulator of calcification and decalcification. clodronate’s use has de...

    Categories: Drugs for Treatment of Bone Diseases
  4. Drug

    Latanoprostene bunod

    go.drugbank.com/drugs/DB11660
    Approved

    Conversely however, latanoprostene bunod integrates an NO-donating moiety in lieu of the isopropyl ester typically found in latanoprost. … As of November 2, 2017 the FDA approved Bausch + Lomb's Vyzulta (latanoprostene bunod opthalmic solution), 0.024% for the indication of reducing intraocular pressure in patients with open-angle glaucoma

  5. Drug

    Gepotidacin

    go.drugbank.com/drugs/DB12134
    ApprovedInvestigational

    [L52680,L52685] In December later the same year, the FDA approved another indication for gepotidacin for the treatment of uncomplicated urogenital gonorrhea. [L54803] … [A273755] By inhibiting two distinct bacterial enzymes, a lower potential for the development of resistance to gepotidacin is expected.

    Categories: Antibacterials for Systemic Use, Antiinfectives for Systemic Use
  6. Drug

    Estradiol valerate

    go.drugbank.com/drugs/DB13956
    ApprovedInvestigationalVet approved

    Estradiol valerate is commercially available as an intramuscular injection as the product Delestrogen and is indicated for the treatment of moderate to severe vasomotor symptoms and vulvovaginal atrophy … due to menopause, for the treatment of hypoestrogenism due to hypogonadism, castration or primary ovarian failure, and for the treatment of advanced androgen-dependent carcinoma of the prostate (for palliation

    Categories: Hormonal Contraceptives for Systemic Use, P-glycoprotein substrates
  7. Drug

    Bicalutamide

    go.drugbank.com/drugs/DB01128
    ApprovedInvestigational

    Bicalutamide is an oral non-steroidal anti-androgen for prostate cancer. It is comprised of a racemic mixture that is a 50:50 composition of the (R)-bicalutamide and (S)-bicalutamide enantionmers. … Bicalutamide binds to the androgen receptor.

    Categories: Androgen Receptor Antagonists, Androgen Receptor InhibitorsProducts: Van-bicalutamide, Ran-bicalutamide
  8. Target

    Nuclear receptor subfamily 1 group I member 2

    go.drugbank.com/bio_entities/BE0000956
    TargetHumans

    Nuclear receptor that acts as a transcription factor regulating genes involved in the metabolism and excretion of xenobiotics, drugs, and endogenous compounds. … Upon ligand binding, translocates to the nucleus, forms a heterodimer with the retinoid X receptor/RXR, and binds to response elements in target promoters, leading to transcriptional activation.

    Polypeptides: Nuclear receptor subfamily 1 group I member 2Synonyms: Pregnane X receptor, Orphan nuclear receptor PAR1
  9. Target

    Gamma-aminobutyric acid type B receptor subunit 2

    go.drugbank.com/bio_entities/BE0002340
    TargetHumans

    Pre-synaptic GABA receptor inhibits neurotransmitter release by down-regulating high-voltage activated calcium channels, whereas postsynaptic GABA receptor decreases neuronal excitability by activating … Within the heterodimeric GABA receptor, only GABBR1 seems to bind agonists, while GABBR2 mediates coupling to G proteins (PubMed:18165688).

    Polypeptides: Gamma-aminobutyric acid type B receptor subunit 2Synonyms: GABA-B receptor 2, G protein-coupled receptor 51
  10. Target

    Nuclear receptor subfamily 1 group I member 3

    go.drugbank.com/bio_entities/BE0003848
    TargetHumans

    Binds and transactivates the retinoic acid response elements that control expression of the retinoic acid receptor beta 2 and alcohol dehydrogenase 3 genes.

    Polypeptides: Nuclear receptor subfamily 1 group I member 3Synonyms: Orphan nuclear receptor MB67, Constitutive androstane receptor